Summary
9.10 -0.19(-2.05%)05/20/2024
Theravance Biopharma Inc (TBPH)
Theravance Biopharma Inc (TBPH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.42 | 13.52 | 1.38 | 12.52 | -1.64 | -15.53 | -60.86 | -58.32 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 9.57 | |
| Open | 9.62 | |
| High | 9.72 | |
| Low | 9.42 | |
| Volume | 245,120 | |
| Change | -0.04 | |
| Change % | -0.42 | |
| Avg Volume (20 Days) | 379,950 | |
| Volume/Avg Volume (20 Days) Ratio | 0.65 | |
| 52 Week Range | 8.22 - 11.98 | |
| Price vs 52 Week High | -20.12% | |
| Price vs 52 Week Low | 16.42% | |
| Range | -0.52 | |
| Gap Up/Down | -0.75 | |
Fundamentals | ||
| Market Capitalization (Mln) | 443 | |
| EBIDTA | -53,188,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.0500 | |
| WallStreet Target Price | 15.40 | |
| Book Value | 4.4290 | |
| Earnings Per Share | -1.0000 | |
| EPS Estimate Current Quarter | -0.1500 | |
| EPS Estimate Next Quarter | -0.2500 | |
| EPS Estimate Current Year | -0.6800 | |
| EPS Estimate Next Year | -0.4000 | |
| Diluted EPS (TTM) | -1.0000 | |
| Revenues | ||
| Profit Marging | -0.9612 | |
| Operating Marging (TTM) | -0.3553 | |
| Return on asset (TTM) | -0.0673 | |
| Return on equity (TTM) | -0.1686 | |
| Revenue TTM | 57,424,000 | |
| Revenue per share TTM | 1.0380 | |
| Quarterly Revenue Growth (YOY) | 0.1990 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -12,046,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 7.1839 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.1909 | |
| Revenue Enterprise Value | 7.1990 | |
| EBITDA Enterprise Value | -9.6898 | |
| Shares | ||
| Shares Outstanding | 48,560,000 | |
| Shares Float | 15,864,973 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.26 | |
| Insider (%) | 14.51 | |
| Institutions (%) | 103.31 | |
05/14 13:10 EST - zacks.com
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.
05/13 18:58 EST - seekingalpha.com
Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2024 Earnings Call Transcript May 13, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Julian Harrison - BTIG David Risinger - Leerink Partners Marc Frahm - TD Cowen Operator Ladies and gentlemen, good afternoon.
Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2024 Earnings Call Transcript May 13, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Julian Harrison - BTIG David Risinger - Leerink Partners Marc Frahm - TD Cowen Operator Ladies and gentlemen, good afternoon.
05/13 18:15 EST - zacks.com
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
05/13 16:05 EST - prnewswire.com
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting margin improvement Continued progress for ampreloxetine CYPRESS enrollment Virtual ampreloxetine KOL event scheduled for May 23, 2024 Q1 2024 ending cash balance of $100 million DUBLIN , May 13, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024. "Building on recent momentum, the Theravance commercial team again delivered a solid quarter of YUPELRI hospital sales execution in the first quarter, setting us on a path to contribute significantly to the product's overall growth in 2024", said Rick E Winningham, Chief Executive Officer.
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting margin improvement Continued progress for ampreloxetine CYPRESS enrollment Virtual ampreloxetine KOL event scheduled for May 23, 2024 Q1 2024 ending cash balance of $100 million DUBLIN , May 13, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024. "Building on recent momentum, the Theravance commercial team again delivered a solid quarter of YUPELRI hospital sales execution in the first quarter, setting us on a path to contribute significantly to the product's overall growth in 2024", said Rick E Winningham, Chief Executive Officer.
05/09 06:00 EST - prnewswire.com
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN , May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT (8:30 AM PDT / 4:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN , May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT (8:30 AM PDT / 4:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.
04/29 06:00 EST - prnewswire.com
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.
04/15 14:19 EST - investorplace.com
BTIG Research Predicts Over 118% Rally for These 3 Stocks
The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ: SMCI ) leading the way with a 216% gain so far.
BTIG Research Predicts Over 118% Rally for These 3 Stocks
The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ: SMCI ) leading the way with a 216% gain so far.
04/15 08:51 EST - zacks.com
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
04/10 06:00 EST - prnewswire.com
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
DUBLIN , April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape for MSA patients with symptomatic nOH.
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
DUBLIN , April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape for MSA patients with symptomatic nOH.
03/27 12:36 EST - zacks.com
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
03/12 15:59 EST - investorplace.com
Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics
The life of a bearish speculator can be dangerous and that's part of the appeal of short-squeeze stocks: you can make life miserable for those attempting to cynically extract profits from others' misery. At the most elemental level, I suppose it's like watching a lion eating a safari hunter.
Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics
The life of a bearish speculator can be dangerous and that's part of the appeal of short-squeeze stocks: you can make life miserable for those attempting to cynically extract profits from others' misery. At the most elemental level, I suppose it's like watching a lion eating a safari hunter.
02/27 12:51 EST - zacks.com
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time.
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time.
02/26 21:52 EST - seekingalpha.com
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
02/26 18:26 EST - zacks.com
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.21 per share a year ago.
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.21 per share a year ago.
02/26 16:05 EST - prnewswire.com
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million 1 Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4 , with Non-GAAP Net Profit of $1.4 million 2 Completed $325 million capital return program, reducing shares outstanding by 37% Ampreloxetine investor event planned for Q2 2024 DUBLIN , Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023. "The Theravance team delivered a strong performance in 2023, having achieved our financial objectives in the fourth quarter and exceeded our aggressive annual goal for YUPELRI hospital growth," said Rick E Winningham, Chief Executive Officer.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million 1 Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4 , with Non-GAAP Net Profit of $1.4 million 2 Completed $325 million capital return program, reducing shares outstanding by 37% Ampreloxetine investor event planned for Q2 2024 DUBLIN , Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023. "The Theravance team delivered a strong performance in 2023, having achieved our financial objectives in the fourth quarter and exceeded our aggressive annual goal for YUPELRI hospital growth," said Rick E Winningham, Chief Executive Officer.
02/14 06:00 EST - prnewswire.com
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on Monday, February 26, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on Monday, February 26, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.
01/12 11:19 EST - zacks.com
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
01/05 08:37 EST - proactiveinvestors.com
Theravance Biopharma shares down on lung disease trial failure
Theravance Biopharma shares fell more than 20% after the company reported that its therapeutic for chronic obstructive pulmonary disease (COPD), a common lung disease, failed a clinical trial.  Its stock was down 20.7% at US$9.14 before Friday's opening bell.
Theravance Biopharma shares down on lung disease trial failure
Theravance Biopharma shares fell more than 20% after the company reported that its therapeutic for chronic obstructive pulmonary disease (COPD), a common lung disease, failed a clinical trial.  Its stock was down 20.7% at US$9.14 before Friday's opening bell.
01/05 06:15 EST - marketwatch.com
Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal
Theravance Biopharma Inc.'s stock TBPH, -0.60% tumbled 21% early Friday,ter the biotech said a Phase 4 trial of its Yupelri treatment for patients with severe to very severe Chronic Obstructive Pulmonary Disease, or COPD, failed to meet its main goal. The trial dubled PFIR-2 aimed to show greater improvement in lung function for Yupelri delivered by standard jet nebulizer compared to Spiriva delivered via a dry powder inhaler in adults with COPD.
Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal
Theravance Biopharma Inc.'s stock TBPH, -0.60% tumbled 21% early Friday,ter the biotech said a Phase 4 trial of its Yupelri treatment for patients with severe to very severe Chronic Obstructive Pulmonary Disease, or COPD, failed to meet its main goal. The trial dubled PFIR-2 aimed to show greater improvement in lung function for Yupelri delivered by standard jet nebulizer compared to Spiriva delivered via a dry powder inhaler in adults with COPD.